American Regent, Inc., a Daiichi Sankyo Group company, today announced results from the phase 3 HEART-FID trial of INJECTAFER® (ferric carboxymaltose injection) for the treatment of iron deficiency in adult heart
Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, have announced that the U.S. Food and Drug Administration (FDA) approved INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure categorized as New York Heart Association class II/III to improve exercise capacity. The company reported that with this approval, INJECTAFER is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency.
INJECTAFER is now the first and only intravenous iron replacement therapy indicated for adult patients with heart failure who have iron deficiency
. | June 5, 2023
American Regent Launches a New Vial Presentation prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ American Regent, Inc. and Provepharm Life Solutions are pleased to announce the availability of ProvayBlue® (methylene blue) Injection, USP in.